Back to Results
First PageMeta Content
Respiratory therapy / Chronic lower respiratory diseases / Chronic obstructive pulmonary disease / Smoking / Asthma / Spirometry / Acute exacerbation of chronic obstructive pulmonary disease / Clinical trial / Pulmonology / Medicine / Health


FDA Advisory Committee Briefing Document: BREO ELLIPTA (Fluticasone Furoate/Vilanterol Inhalation Powder) for Treatment of COPD
Add to Reading List

Open Document

File Size: 2,14 MB

Share Result on Facebook

City

Research Triangle Park / /

Company

GlaxoSmithKline Inc. / Clinical Laboratory / AEs / ITT / /

Event

FDA Phase / Product Recall / Product Issues / /

IndustryTerm

Treatment of Chronic Obstructive Pulmonary Disease / /

MedicalCondition

Asthma Studies / Pneumonia / IN COPD / Primary COPD Studies / Bone Disorders / COPD / On-Treatment Pneumonia / Pneumonias / Disorders / Asthma / /

Organization

FDA / Pulmonary-Allergy Drugs Advisory Committee / /

Product

Study / COPD / Fluticasone Furoate/Vilanterol Inhalation Powder / /

ProvinceOrState

North Carolina / /

PublishedMedium

24 Hours / Baseline / /

Technology

Pharmacokinetics / Pharmacodynamics / /

SocialTag